An acquired translocation in JAK2 Val617Phe-negative essential thrombocythemia associated with autosomal spread of X-inactivation

Haematologica

Volumn 91, Issue 8, 2006, Pages 1100-1104

  Vassiliou, George S ^a   Campbell, Peter J ^a   Li, Juan ^a   Roberts, Ian ^b   Swanton, Soheila ^e   Huntly, Brian J P ^a   Fourouclas, Nasios ^a   Baxter, E Joanna ^a   Munro, Laura R ^c   Culligan, Dominic A ^c   Scott, Linda M ^a   Green, Anthony R ^a,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e NONE

Author keywords

5q minus syndrome; Autosomal spread of X inactivation; Essential thrombocythemia; JAK2 Val617Phe negative

Indexed keywords

AMINO ACID; JANUS KINASE 2;

ADULT; ANAMNESIS; ARTICLE; BREAST CANCER; CASE REPORT; CELL ISOLATION; CHROMOSOME ANALYSIS; CHROMOSOME BAND; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION; CHROMOSOME WALKING; CLINICAL FEATURE; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE IDENTIFICATION; GENE MUTATION; GENE SILENCING; GENE TRANSLOCATION; HUMAN; MONONUCLEAR CELL; MYELOPROLIFERATIVE DISORDER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; X CHROMOSOME;

AMINO ACID SUBSTITUTION; BASE SEQUENCE; BLOTTING, SOUTHERN; BONE MARROW; BREAST NEOPLASMS; CHROMOSOME DISORDERS; CHROMOSOME MAPPING; CHROMOSOME WALKING; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, X; DNA METHYLATION; DNA PRIMERS; FEMALE; HUMANS; JANUS KINASE 2; MIDDLE AGED; PHENYLALANINE; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEX CHROMOSOME DISORDERS; THROMBOCYTHEMIA, HEMORRHAGIC; TRANSLOCATION, GENETIC; VALINE;

EID: 33746987553     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Barbui T, Finazzi G. Chronic myeloproliferative disorders. In: Spivak JL, Barosi G, Tognoni G, Barbui T, Finazzi G, Marchioli R, et al. eds. Hematology (Am Soc Hematol Educ Program); 2003. p. 200-4.
2. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
3. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
4. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434: 1144-8.
5. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
6. Anonymous. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium. Cell 1994;77:881-94.
7. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14.
8. Munro LR, Stevenson DA, Culligan DJ. Translocation (X;5)(q13;q33) in essential thrombocythemia. Cancer Genet Cytogenet 1999;114:78-9.
9. O'Reilly J, Crawford J, Uzaraga J, Cannell P. Translocation (X;20) involving the inactive X chromosome in a patient with myeloproliferative disorder. Cancer Genet Cytogenet 2005; 158:81-3.
10. Reddy KS, Richkind K, Ross M, Seirra R. Translocation (X;20)(q13;q13.3): a nonrandom abnormality in four patients with myeloid disorders. Cancer Genet Cytogenet 2005;157:70-3.
11. Bench AJ, Nacheva EP, Hood TL, Holden JL, French L, Swanton S, et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene 2000;19:3902-13.
12. nd ed. 1989.
13. Roberts I, Foster N, Nacheva E, Coleman N. Paint-assisted microdissection-FISH: Rapid and simple mapping of translocation breakpoints in the embryonal rhabdomyosarcoma cell line RD. Cytometry A 2004;58: 177-84.
14. Li J, Bench AJ, Vassiliou GS, Fourouclas N, Ferguson-Smith AC, Green AR. Imprinting of the human L3MBTL gene, a polycomb family member located in a region of chromosome 20 deleted in human myeloid malignancies. Proc Natl Acad Sci USA 2004; 101:7341-6.
15. Pearson TC, Messinezy M, Westwood N, Green AR, Bench AJ, Huntly BJ, et al. A polycythemia vera update: diagnosis, pathobiology, and treatment. Hematology (Am Soc Hematol Educ Program) 2000:51-68.
16. Carrel L, Cottle AA, Goglin KC, Willard HF. A first-generation X-inactivation profile of the human X chromosome. Proc Natl Acad Sci USA 1999; 96:14440-4.
17. Sharp AJ, Spotswood HT, Robinson DO, Turner BM, Jacobs PA. Molecular and cytogenetic analysis of the spreading of X inactivation in X;autosome translocations. Hum Mol Genet 2002; 11:3145-56.
18. Brown CJ, Wulard HE The human X-inactivation centre is not required for maintenance of X-chromosome inactivation. Nature 1994;368:154-6.
19. Hall LL, Byron M, Sakai K, Carrel L, Willard HF, Lawrence JB. An ectopic human XIST gene can induce chromosome inactivation in postdifferentiation human HT-1080 cells. Proc Natl Acad Sci USA 2002;99:8677-82.
20. Kleinjan DA, Seawright A, Schedl A, Quinlan RA, Danes S, van Heyningen V. Aniridia-associated translocations, DNase hypersensitivity, sequence comparison and transgenic analysis redefine the functional domain of PAX6. Hum Mol Genet 2001;10:2049-59.
21. Gray BA, Cornfield D, Bent-Williams A, Zori RT. Translocation (X;20) (q13.1;q13.3) as a primary chromosomal finding in two patients with myelocytic disorders. Cancer Genet Cytogenet 2003;141:169-74.
22. Chen Z, Richkind K, Roherty S, Velasco J, Lytle C, Brothman AR, et al. A group of previously not recognized cytogenetic abnormalities in myeloid hematological malignancies. Cancer Genet Cytogenet 1999;113:162-5.